NOXOPHARM LIMITED — Capital/Financing Update 2018

Mar 28, 2018

==> picture [180 x 77] intentionally omitted <==

Date: 29 March 2018

Sydney, Australia

ASX: NOX

Noxopharm Limited

ASX Limited 20 Bridge Street SYDNEY NSW 2000

ABN 50 608 966 123

NOTICE UNDER SECTION 708A(5)(E) OF THE CORPORATIONS ACT 2001 (CTH)

Registered Office:

Suite 3, Level 4 828 Pacific Highway Gordon NSW 2072 Australia

Operational Office:

Suite 3, Level 4 828 Pacific Highway Gordon NSW 2072 Australia

Noxopharm Limited (ASX: NOX) ( Noxopharm or the Company ) has today issued 7,264,966 new fully paid ordinary shares in the Company ( New Shares ) to Sophisticated and Professional Investors, at an issue price of A$0.90 per New Share. The New Shares were issued under the Private Placement detailed in the ASX announcement ASX on 23 March 2018.

Please see attached Appendix 3B for more details.

NOX gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) that:

• 1 The New Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act.

• 2 As at the date of this notice, NOX has complied with:

Board of Directors

Mr Peter Marks

Chairman Non-Executive Director

Dr Graham Kelly Chief Executive Officer Managing Director

Dr Ian Dixon Non-Executive Director

• (a) The provisions of Chapter 2M of the Corporations Act as they apply to NOX; and

• (b) Section 674 of the Corporations Act.

• 3 As at the date of this notice, there is no information that is “excluded information” of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act that is required to be disclosed by the Company under section 708A(6)(e) of the Corporations Act.

For and on behalf of the Board,

Yours faithfully,

==> picture [105 x 61] intentionally omitted <==

David Franks Company Secretary